These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9552353)

  • 1. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.
    Wiederrecht GJ; Sabers CJ; Brunn GJ; Martin MM; Dumont FJ; Abraham RT
    Prog Cell Cycle Res; 1995; 1():53-71. PubMed ID: 9552353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
    Sabers CJ; Martin MM; Brunn GJ; Williams JM; Dumont FJ; Wiederrecht G; Abraham RT
    J Biol Chem; 1995 Jan; 270(2):815-22. PubMed ID: 7822316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of the immunosuppressant rapamycin.
    Dumont FJ; Su Q
    Life Sci; 1996; 58(5):373-95. PubMed ID: 8594303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.
    Abraham RT
    Curr Opin Immunol; 1998 Jun; 10(3):330-6. PubMed ID: 9638370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
    Brown EJ; Albers MW; Shin TB; Ichikawa K; Keith CT; Lane WS; Schreiber SL
    Nature; 1994 Jun; 369(6483):756-8. PubMed ID: 8008069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.
    Zheng XF; Florentino D; Chen J; Crabtree GR; Schreiber SL
    Cell; 1995 Jul; 82(1):121-30. PubMed ID: 7606777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
    Lorenz MC; Heitman J
    J Biol Chem; 1995 Nov; 270(46):27531-7. PubMed ID: 7499212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin.
    Cardenas ME; Zhu D; Heitman J
    Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):472-7. PubMed ID: 8591053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma.
    Dumont FJ; Staruch MJ; Grammer T; Blenis J; Kastner CA; Rupprecht KM
    Cell Immunol; 1995 Jun; 163(1):70-9. PubMed ID: 7538911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
    Cafferkey R; Young PR; McLaughlin MM; Bergsma DJ; Koltin Y; Sathe GM; Faucette L; Eng WK; Johnson RK; Livi GP
    Mol Cell Biol; 1993 Oct; 13(10):6012-23. PubMed ID: 8413204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.
    Brunn GJ; Williams J; Sabers C; Wiederrecht G; Lawrence JC; Abraham RT
    EMBO J; 1996 Oct; 15(19):5256-67. PubMed ID: 8895571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin resistance in ataxia-telangiectasia.
    Beamish H; Williams R; Chen P; Khanna KK; Hobson K; Watters D; Shiloh Y; Lavin M
    Oncogene; 1996 Sep; 13(5):963-70. PubMed ID: 8806686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability.
    Hashemolhosseini S; Nagamine Y; Morley SJ; Desrivières S; Mercep L; Ferrari S
    J Biol Chem; 1998 Jun; 273(23):14424-9. PubMed ID: 9603954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
    Sabatini DM; Erdjument-Bromage H; Lui M; Tempst P; Snyder SH
    Cell; 1994 Jul; 78(1):35-43. PubMed ID: 7518356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An FKBP-rapamycin-sensitive, cyclin-dependent kinase activity that correlates with the FKBP-rapamycin-induced G1 arrest point in MG-63 cells.
    Albers MW; Brown EJ; Tanaka A; Williams RT; Hall FL; Schreiber SL
    Ann N Y Acad Sci; 1993 Nov; 696():54-62. PubMed ID: 8109857
    [No Abstract]   [Full Text] [Related]  

  • 16. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue.
    Stan R; McLaughlin MM; Cafferkey R; Johnson RK; Rosenberg M; Livi GP
    J Biol Chem; 1994 Dec; 269(51):32027-30. PubMed ID: 7528205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity.
    Cardenas ME; Heitman J
    EMBO J; 1995 Dec; 14(23):5892-907. PubMed ID: 8846782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural roles of immunophilins and their ligands.
    Sabatini DM; Lai MM; Snyder SH
    Mol Neurobiol; 1997 Oct; 15(2):223-39. PubMed ID: 9396011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of rapamycin (Sirolimus, Rapamune).
    Molnar-Kimber KL
    Transplant Proc; 1996 Apr; 28(2):964-9. PubMed ID: 8623482
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporin A, FK506 and rapamycin: more than just immunosuppression.
    Kunz J; Hall MN
    Trends Biochem Sci; 1993 Sep; 18(9):334-8. PubMed ID: 7694398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.